BioSpace News Archive

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the third quarter of 2022 after the close of trading on Tuesday, November 8, 2022.

Veracyte, Inc. (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer, respectively, were presented as posters today at the American College of Chest Physicians (CHEST) Annual Meeting 2022.

Denali Therapeutics Inc. announced that it intends to offer and sell $250 million of shares of its common stock in an underwritten public offering.

Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, has amended terms of its loans with Richard Jeffs, the Company’s major shareholder and largest financier.

Radiopharm Theranostics is pleased to announce that Imperial College London’s F-18 Pivalate has achieved successful Phase 2a data in patients with brain metastases, having shown significant tumour uptake that was consistent and independent from the tumour origin.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “TELO”) is pleased to announce that it has recently engaged Richard A. Bender MD, FACP, a veteran multiple myeloma (“MM”) clinician, key opinion leader and medical diagnostics expert to establish and chair TELO’s MM clinical advisory board (the “Advisory Board”).

SOHM, Inc., a generic pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces that it has signed a memorandum of understanding with SRAM & MRAM Group for injections of required funds for the Company’s various new pipeline projects.

QuantaMatrix, an in vitro diagnostics company specializing in the discovery, development and commercialization of fully integrated solutions within the sepsis value chain, today announces that its dRAST™ solution has been adopted for routine clinical use by admed, a Swiss-based laboratory.

Promatix, a London-based oncology drug discovery and development company that uses multi-omics to identify novel therapeutics, today announced a collaboration with the laboratory of Professor Jasmin Fisher to develop new proprietary computational executable cancer models for Promatix’s CipherPro suite of algorithms to mine the TxPro databank and identify new oncology drug targets.

Australian industrial biotechnology leader MicroBioGen (“the Company”) officially opened its state-of-the-art laboratories in Macquarie Park in Northern Sydney this weekend. The labs will produce world-leading micro-organisms that are essential to industries worth over US$2 trillion per year, including biofuels, alternative proteins, space exploration, sustainable human foods and animal feed.